An interventional study of FSMP and Nutritional counseling in Breast Cancer, sponsored by Flavolife Srl. Recruiting at 1 site in Italy. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Flavolife Srl · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to compare the effect of a Food for Special Medical Purposes (FSMP) mainly containing amino acids and flavonoids in combination with nutritional counseling, versus nutritional counseling alone, on chemotherapy toxicity, nutritional status and quality of life in patients with breast cancer.
The main questions it aims to answer are:
Researchers will compare a similar group of participants only receiving the nutritional counseling to see if any difference occurs.
Participants will be selected at the first oncological visit at the Outpatient Clinics or the Department of Medical Oncology of the IRCCS Policlinico San Matteo of Pavia. The doctor, evaluated the inclusion and exclusion criteria, will propose patient to participate in the study and, after obtaining informed consent, will proceed with enrollment. On the first day of chemotherapy, participants will undergo an oncological and nutritional examination, with collection of anthropometric data, assessment of body composition, assessment of quality of life through special validated questionnaires, blood sampling for blood chemistry tests and urine collection. Participants in the treated group will receive a supply of the FSMP to take home. At check-up visits, the participant's nutritional status and any adverse events will be assessed, other than adherence to treatment by delivery of empty product boxes and chemotherapy compliance. Blood chemistry tests will be repeated at 6 weeks after the first chemotherapy cycle and 3 weeks after the last chemotherapy cycle (follow-up period).
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 60 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →This is the only study on the registry with Flavolife Srl as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Nutritional counseling plus one sachet of the study product (6.5 g) per day, away from meals, starting the day after the first chemotherapy cycle until three weeks after the last chemotherapy cycle (for a total of 12 weeks)
Dietary Supplement: FSMP · Other: Nutritional counseling
Nutritional counseling
Other: Nutritional counseling
Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
Mean change from baseline in High-Sensitivity Troponin Levels as a serological marker of chemotherapy cardiotoxicity
The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model
Time frame: 0, 6, 12 weeks
Mean change from baseline in weight, Body Mass Index (BMI) and Fat Free Mass Index (FFMI)
Participant's weight in kilograms and height in meters will be combined to report BMI and FFMI in kg/m\^2
Time frame: 0, 3, 6, 9, 12 weeks
Mean change from baseline in Phase Angle
Participant's body composition will be evaluated through measurement of the phase angle which represents the relationship between resistance and capacitive reactance of the body and bioimpedance diagnostics
Time frame: 0, 3, 6, 9, 12 weeks
Mean change from baseline in Bioelectrical Impedance Vector Analysis (BIVA)
Participant's water and nutritional status will be evaluated
Time frame: 0, 3, 6, 9, 12 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Proportion of participants with adverse events of any type and specifically haematological, cardiac, gastrointestinal, hepatobiliary, metabolic, psychiatric, renal and urinary types, distinguishing between grade 1-2, grade 3-4 and grade 5. Furthermore, the proportion of participants who discontinue chemotherapy treatment and the change in the number of participants who reduce their chemotherapy dose during the treatment
Time frame: 3, 6, 9, 12 weeks
Mean change from baseline in Interleukine-6 levels
The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model
Time frame: 0, 6, 12 weeks
Mean change from baseline Interleukine-1 beta levels
The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model
Time frame: 0, 6, 12 weeks
Mean change from baseline in C-reactive Protein levels
The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model
Time frame: 0, 6, 12 weeks
Participant's perception of her physical and mental state
Comparison of the total average values resulting from the compilation of two validated oncological questionnaires, which include questions with scores from 1 to 4, where in general higher scores mean a worse outcome
Time frame: 0, 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.